H

HK Inno.N Corp
KOSDAQ:195940

Watchlist Manager
HK Inno.N Corp
KOSDAQ:195940
Watchlist
Price: 37 750 KRW -2.83% Market Closed
Market Cap: 1.1T KRW
Have any thoughts about
HK Inno.N Corp?
Write Note

HK Inno.N Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HK Inno.N Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
H
HK Inno.N Corp
KOSDAQ:195940
Cash & Cash Equivalents
â‚©107.7B
CAGR 3-Years
28%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cash & Cash Equivalents
â‚©229.7B
CAGR 3-Years
5%
CAGR 5-Years
-3%
CAGR 10-Years
3%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash & Cash Equivalents
â‚©239.7B
CAGR 3-Years
59%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Cash & Cash Equivalents
â‚©48.2B
CAGR 3-Years
-38%
CAGR 5-Years
-12%
CAGR 10-Years
-6%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash & Cash Equivalents
â‚©134B
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
14%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cash & Cash Equivalents
â‚©28.1B
CAGR 3-Years
-23%
CAGR 5-Years
66%
CAGR 10-Years
28%
No Stocks Found

HK Inno.N Corp
Glance View

Market Cap
1.1T KRW
Industry
Pharmaceuticals

HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.

Intrinsic Value
70 702.26 KRW
Undervaluation 47%
Intrinsic Value
Price
H

See Also

What is HK Inno.N Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
107.7B KRW

Based on the financial report for Dec 31, 2023, HK Inno.N Corp's Cash & Cash Equivalents amounts to 107.7B KRW.

What is HK Inno.N Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
15%

Over the last year, the Cash & Cash Equivalents growth was -3%. The average annual Cash & Cash Equivalents growth rates for HK Inno.N Corp have been 28% over the past three years , 15% over the past five years .

Back to Top